Key Points – Q2 revenue rose 1% to $93.3 million, as 4% software growth and stronger bookings offset a 3% decline in services revenue.
Software now represents 53% of the business, while services bookings were pressured partly by the Regulatory and Medical Writing divestiture. – Certara reaffirmed its 2026 revenue outlook of $367 million to $382 million, but lowered its adjusted EBITDA margin forecast to 29%–31% from 30%–32% because of divestiture-related stranded costs and business-mix changes. – The company is pursuing significant operational and commercial changes, including a workforce reduction expected to deliver about $13 million in annualized savings, a new commercial organization and expanded AI initiatives
Certara also completed a $100 million stock-repurchase program and authorized an additional $50 million. – 3 Momentum Stocks That Could Soar Post-Market Volatility Certara (NASDAQ:CERT) reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy. Chief Executive Officer Jon Resnick said the quarter was focused on executing the company’s plan to build a business capable of sustainable double-digit growth.
He said Certara’s market backdrop remains favorable, citing biopharma spending, clinical trial starts and regulatory guidance supporting model-informed drug development. Software Growth Offsets Services Decline – Simulations Plus Stock Drops 15% Despite EPS Beat Software revenue rose 4% year over year to $48.8 million, driven by Simcyp, Phoenix and Pinnacle 21. Software bookings increased 9% to $50.7 million, while trailing 12-month software bookings rose 8% to $196.4 million.